Cardiovascular disease and subsequent risk of psychiatric disorders: a nationwide sibling-controlled study

Qing Shen, Huan Song, Thor Aspelund, Jingru Yu, Donghao Lu, Jóhanna Jakobsdóttir, Jacob Bergstedt, Lu Yi, Patrick F. Sullivan, Arvid Sjölander, Weimin Ye, Katja Fall, Fang Fang, Unnur Valdimarsdóttir
doi: https://doi.org/10.1101/2022.06.27.22276962

Abstract

Background The association between cardiovascular disease (CVD) and selected psychiatric disorders has frequently been suggested while inadequate control of familial factors and comorbidities has halted causal inferences.

Methods We identified 869 056 patients newly diagnosed with CVD from 1987 to 2016 in Sweden while no history of psychiatric disorders, and 910 178 full siblings of these patients and 10 individually age- and sex-matched unrelated population controls (N=8 690 560). Adjusting for multiple comorbid conditions, we used flexible parametric models and Cox regression to estimate the association of CVD with risk of all subsequent psychiatric disorders, comparing rates of first incident psychiatric disorder among CVD patients with rates among unaffected full siblings and population controls.

Results The median age at diagnosis was 60 years for patients with cardiovascular disease and 59.2% were male. During up to thirty years of follow-up, the crude incidence rates of psychiatric disorder were 7.1, 4.6 and 4.0 per 1000 person-years for patients with cardiovascular disease, their siblings and population controls. In the sibling comparison, we observed an increased risk of psychiatric disorder during the first year after cardiovascular diagnosis (hazard ratio [HR], 2.74; 95% confidence interval [CI], 2.62-2.87) and thereafter (1.45; 95% CI, 1.42-1.48). Increased risks were observed for all types of psychiatric disorders and among all diagnoses of cardiovascular disease. We observed similar associations in the population comparison. Cardiovascular patients who developed a comorbid psychiatric disorder during the first year after diagnosis were at increased risk of subsequent cardiovascular death compared to patients without such comorbidity (HR 1.55; 95% CI 1.44-1.67).

Conclusions Patients diagnosed with cardiovascular disease are at an elevated risk for subsequent psychiatric disorders independent of familial factors and comorbid conditions. Cardiovascular patients with comorbid psychiatric disorders are at increased risk of cardiovascular mortality suggesting that surveillance and treatment of psychiatric comorbidities should be considered as an integral part of clinical management of newly diagnosed patients with cardiovascular disease.

Funding this work was supported by the EU Horizon 2020 Research and Innovation Action Grant (CoMorMent, Grant nr. 847776 to UV, PFS and FF), Grant of Excellence, Icelandic Research Fund (grant no. 163362-051 to UV), ERC Consolidator Grant (StressGene, grant no: 726413 to UV), Swedish Research Council (Vetenskapsrådet, award D0886501 to PFS) and US NIMH R01 MH123724 (to PFS).

Introduction

Being diagnosed and living with a major life-threatening disease is stressful and associated with multiple biologic processes that combined may contribute to the development of psychiatric disorders. It is for instance firmly demonstrated that a cancer diagnosis is associated with a rapid rise of psychiatric disorders1 and self-inflicted injury,2 which further is associated with a compromised cancer specific survival.3 Psychiatric comorbidities have also been reported among patients with cardiovascular disease (CVD), e.g. after stroke,4 heart failure,5 and myocardial infarction.6,7 with indications of elevated risk of overall mortality.8,9 Yet, evidence on the association between CVD and subsequent development of psychiatric disorders is still limited as previous research has mainly relied on selected patient populations instead of complete follow-up of general population as well as limited control of reverse causality and important confounding factors, e.g. familial factors and comorbidities.10–12

We thoroughly searched the existing literature of investigating the association between CVD and clinically confirmed psychiatric disorders or psychiatric symptoms. After excluding most studies with either cross-sectional or retrospective designs, we only found 12 prospective cohort studies investigating the risk of selected psychiatric disorders following diagnosis of cardiovascular disease (summarized in Table S1, Supplementary Appendix). While these prospective studies suggest a positive association between hypertension, heart disease, and stroke with depressive symptoms11,13–15 and stress-related disorders,16 they were limited to elderly populations,17,18 and using self-reported ascertainment of psychiatric outcomes.17,18 Only few of these studies addressed incident or first diagnosed psychiatric disorders among patients with CVD, e.g. exlcuding patients with history of psychiatric disorders, and no study addressed the issue of familial confounding. Indeed, genetic correlation between these two complex diseases have recently been documented 19–21 as well as the importance of early life environment for the development of both cardiovascular disease22 and psychiatric disorders.23 It is therefore unknown whether the reported association between CVD and psychiatric disorder can be attributed to unmeasured confounding shared within families.19–21 Thus, a comprehensive evaluation of the association between all CVDs and risk of any incident psychiatric disorder, addressing the abovementioned shortcomings, is warranted.

With up to thirty years of follow-up and with nationwide complete information on family links in Sweden, we aimed to comprehensively investigate the association between CVD diagnosed in specialist care and subsequent risk of incident psychiatric disorders while accounting for familial factors through a sibling comparison. We further aimed to estimate the potential role of psychiatric comorbidity in cardiovascular mortality among patients with CVD.

Materials and Methods

Study Design

The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001.25 The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932.26 Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD that attended in inpatient or outpatient specialized care between 1 January 1987 and 31 December 2016 (N=986 726). Patients diagnosed with CVD before age 5 (N=6 091, probable congenital heart disease) or with a history of any psychiatric disorder before the diagnosis of CVD (N=111 579) were excluded, leaving 869 056 patients in the analysis (Fig S1, Supplementary Appendix). Date of first CVD diagnosis was used as the index date for the exposed patients.

Through the Multi-Generation Register, we identified all full siblings of patients with CVD (58.6% of all CVD patients) who were alive and free of CVD and psychiatric disorder at the time when their affected sibling was diagnosed (N=910 178). In addition, for each patient with CVD, we randomly selected 10 age-and sex-matched individuals from the general population who were free of CVD or psychiatric disorder when the index patient was diagnosed (N=8 690 560). The date of CVD diagnosis for the index patient was used as the index date for their unaffected siblings and matched population controls.

All study participants were followed from the index date until first diagnosis of any psychiatric disorder, death, emigration, first diagnosis of CVD (for unaffected siblings and matched population controls), or the end of the study period (31 December 2016), whichever occurred first.

Ascertainment of Cardiovascular Disease and Psychiatric Disorder

We defined CVD as any first inpatient or outpatient hospital visit with CVD as the primary diagnosis from the Swedish Patient Register. Incident psychiatric disorder was defined as any first inpatient or outpatient hospital visit with psychiatric disorder as the primary diagnosis. We used the 9th and 10th Swedish revisions of the International Classification of Diseases (ICD-9 and 10) codes to identify CVD and psychiatric disorders and their subtypes (Table S2, Supplementary Appendix). In line with previous study,27 we classified CVD as ischemic heart disease, cerebrovascular disease, emboli/thrombosis, hypertensive disease, heart failure, and arrhythmia/conduction disorder. We classified psychiatric disorders as non-affective psychotic disorders, affective psychotic disorders, alcohol or drug misuse, mood disorders excluding psychotic symptoms, anxiety and stress-related disorders, eating disorders, and personality disorders.28

Covariates

We extracted socioeconomic information for each participant, including educational level, individualized family income and cohabitation status, from the Longitudinal Integration Database for Health Insurance and Labor Market.29 Missing information on socioeconomic status was categorized as unknown or missing group. A history of somatic diseases was defined as having any of the following conditions before the index date: chronic pulmonary disease, connective tissue disease, diabetes, renal diseases, liver disease, ulcer diseases, malignancies, and HIV infection/AIDS (Table S2, Supplementary Appendix). We defined a family history of psychiatric disorders as a diagnosis of any psychiatric disorder among biological parents and full siblings of the study participants before the index date according to the Swedish Patient Register.

Statistical Analysis

We used flexible parametric survival models to estimate the time-varying association between CVD and subsequent risk of incident psychiatric disorders,30 by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the association within one year of CVD diagnosis and beyond one year. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were derived from stratified Cox regression models, using time since the index date as the underlying time scale. We estimated HRs for any psychiatric disorder and categories of psychiatric disorders. We performed subgroup analyses by sex, age at index date (<50, 50-60, or >60 years), age at follow-up (<60 or ≥60 years), calendar year at index date (1987-1996, 1997-2006, or 2007-2016), history of somatic diseases (no or yes), and family history of psychiatric disorder (no or yes). In the sibling comparison, all Cox models were stratified by sibling sets and adjusted for sex, birth year, educational level, individualized family income, cohabitation status, and history of somatic diseases. In the population comparison, all Cox models were stratified by the matching variables birth year and sex and adjusted for all abovementioned covariates plus family history of psychiatric disorder.

To study the impact of additional cardiovascular comorbidity (i.e., patients with another type of CVD after diagnosis of the first CVD), we analyzed the association by presence or absence of cardiovascular comorbidity after the index date according to the type of first CVD. This analysis was restricted to follow-up beyond one year to focus on patients who survived their first CVD to be able to receive the diagnosis of another CVD. As a patient with CVD might have different types of CVD, we identified all diagnoses of CVD during follow-up and considered CVD comorbidity as a time-varying variable through splitting the person-time according to each diagnosis.

Because the Swedish Patient Register includes only information related to specialist care, we might have misclassified patients with psychiatric symptoms who were only attended by primary care. In a sensitivity analysis, we excluded also individuals with prescribed use of psychotropic drugs before the index date (ascertained from the Swedish Prescribed Drug Register including information on all prescribed medication use in Sweden since July 2005), and followed the remaining participants during 2006-2016. Use of psychotropic drugs during follow-up was also considered as having psychiatric disorder in this analysis.

To study rate of cardiovascular mortality (ascertained from the Swedish Causes of Death Register) in relation to psychiatric comorbidities after CVD diagnosis, we plotted Kaplan-Meier survival curves beyond the first year of follow-up for CVD patients with or without a diagnosis of psychiatric disorder during the first year of follow-up, separately. In addition to this 1-year time window, we also studied six months or two years since CVD diagnosis, to assess the robustness of these survival curves. We calculated the HRs of cardiovascular mortality for these two groups of patients using Cox regression model.

Analyses were performed in STATA 17.0 (StataCorp LP). All tests were two sided and P<0.05 was used as statistically level of significance. The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32).

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

The median age at index date was 60 years for CVD patients and 55 years for their unaffected full siblings (Table 1). 59.2% of the CVD patients and 48.4% of their unaffected siblings were male. CVD patients were more likely to have a history of somatic diseases than their unaffected siblings and matched population controls (15.6% vs. 8.8% and 11.0%). The most common diagnoses among the CVD patients were ischemic heart diseases (24.5%), arrhythmia/conduction disorders (24.2%), and hypertensive diseases (17.3%). The majority of the CVD patients had only one CVD diagnosis (without additional CVD comorbidities) during follow-up (69.7%).

View this table:
Table 1. Characteristics of CVD patients diagnosed in Sweden between 1987 and 2016, their unaffected siblings and matched population controls.

During up to thirty years of follow-up, the crude incidence rates of psychiatric disorder were 7.1, 4.6 and 4.0 per 1000 person-years among CVD patients, their unaffected full siblings, and matched population controls, respectively (Table S3, Supplementary Appendix). Compared with unaffected siblings, CVD patients showed an increased risk of incident psychiatric disorder, especially immediately after diagnosis (Fig 1). The risk declined rapidly within the first few months after diagnosis and decreased gradually thereafter: the HR was 2.74 (95% CI 2.62 to 2.87) within first year and 1.45 (95% CI 1.42 to 1.48) beyond first year (Table S4, Supplementary Appendix). The risk increment was noted in all types of psychiatric disorders within and beyond first year of follow-up (Fig 2). Overall, the observed risk increase was similar in sibling and population comparisons, although the HR of non-affective psychotic disorders beyond one year of CVD diagnosis was smaller in the sibling comparison than in the population comparison. During the entire follow-up, we found similar positive associations across sex, age at index date, age at follow-up, history of somatic diseases and family history of psychiatric disorders (Table S3). A greater risk increment was observed in recent calendar years than earlier years.

Figure 1.
Figure 1. Time-varying hazard ratios for an incident psychiatric disorder among CVD patients, compared with their unaffected full siblings (sibling comparison) or matched population controls (population comparison), by time of follow-up (<1 year and >=1 year from CVD diagnosis)*

* CVD: cardiovascular disease. Time-varying hazard ratios and 95% confidence intervals were derived from flexible parametric survival models, allowing the effect of psychiatric disorder to vary over time. A spline with 5 df was used for the baseline rate, and 3 df was used for the time-varying effect. All models were adjusted for age at index date, sex, educational level, yearly individualized family income, cohabitation status, history of somatic diseases, as well as family history of psychiatric disorder (for population comparison).

Figure 2.
Figure 2. Hazard ratios with 95% confidence intervals for different types of psychiatric disorder among CVD patients compared with their full siblings and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)*

* CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, controlling for age at index date, sex, educational level, individualized family income, cohabitation status, history of somatic diseases, and family history of psychiatric disorder (in population comparison). Time since index date was used as underlying time scale.

We found an increased risk of incident psychiatric disorder among all groups of CVD patients, with the most marked risk increase observed among patients with cerebrovascular disease and heart failure (Fig 3). A greater risk increase of incident psychiatric disorder was noted among CVD patients with additional cardiovascular comorbidities beyond one year of first CVD diagnosis compared with CVD patients without such comorbidities, except among those with heart failure (Fig S2, Supplementary Appendix). We found a similar positive association between CVD and risk of incident psychiatric disorder, when including use of psychotropic drugs as a definition of psychiatric disorder (Table S5, Supplementary Appendix).

Figure 3.
Figure 3. Hazard ratios with 95% confidence intervals for psychiatric disorders among different groups of CVD patients compared with their full siblings and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)*

* CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, controlling for age at index date, sex, education level, individualized family income, cohabitation status, history of somatic diseases, and family history of psychiatric disorder (in population comparison). Time since index date was used as underlying time scale. We identified all cardiovascular diagnoses during follow-up and considered CVD comorbidity as a time-varying variable by grouping the person-time according to each diagnosis.

CVD patients diagnosed with subsequent psychiatric disorder showed a reduced CVD-specific survival compared with patients without such diagnosis (Fig 4, and Supplementary Appendix Fig S3 and S4). The HR of cardiovascular death was 1.55 (95% CI 1.44 to 1.67) when comparing CVD patients with a diagnosis of psychiatric disorder to patients without such diagnosis (mortality rate, 9.2 and 7.1 per 1 000 person-years, respectively).

Figure 4.
Figure 4. Kaplan-Meier estimates of CVD death in CVD patients with and without incident psychiatric disorder during the first year of follow-up *

* CVD: cardiovascular disease. Time since index date was used as underlying time scale. 90.4% of CVD patients (N=785 287) survived the first year of follow-up and included in this analysis.

Discussion

Our large population-based sibling-controlled cohort study including all patients diagnosed with their first CVD between 1987 and 2016 in Sweden, their unaffected full siblings, as well as a set of randomly selected unaffected population controls reveals a robust association between CVD and subsequent risk of incident psychiatric disorder. We found that patients with CVD were at elevated risk of various types of psychiatric disorders, independent of confounding factors shared within families and history of somatic diseases. The risk increment was greatest during the year after CVD diagnosis, indicating an opportunity for clinical surveillance in a high-risk time window. Further, an occurrence of psychiatric comorbidity after CVD diagnosis was associated with an approximately 55% increased risk of subsequent death from cardiovascular causes. This finding further underscores the importance of surveillance and, if needed, treatment of psychiatric comorbidities among newly diagnosed CVD patients.

Strengths and Limitations

The strengths of our study include its large sample size of the entire Swedish nation and the prospective study design with sibling comparison that significantly alleviates concerns of familial confounding from shared genetic and early-life environmental factors between siblings. The Swedish population and health registers provide the opportunity to obtain complete follow-up as well as prospectively and independently collected information on disease identification, minimizing the risk of selection and information biases. The large sample size of our study further enables detailed subgroup analyses by types of CVD, types of psychiatric disorders, and patient characteristics.

Some limitations need to be acknowledged. First, we identified patients with CVD and psychiatric disorder through inpatient or outpatient hospital visit. The later inclusion of outpatient records in the Swedish Patient Register may lead to underestimation of the actual numbers of patients with CVD and psychiatric disorder, especially those with relatively milder symptoms. Second, we missed individuals attended in primary care, which may underestimate the proportion of individuals with history of psychiatric problems at study entry. To alleviate such concerns, we additionally considered the use of prescribed psychotropic drugs and found similar results. Further, patients with CVD have an established contact with health care and may therefore be more likely than others to be diagnosed with psychiatric disorder. Although such surveillance bias may to some extent explain the increased risks during the first few months after CVD diagnosis, it is unlikely that the risk elevation during the entire follow-up is attributed to such bias. Finally, we could not directly control for lifestyle factors (e.g., smoking, diet, and physical exercise) and therefore cannot exclude the possibility of residual confounding not fully controlled for in the sibling comparison.

Comparison with other studies

Our findings are consistent with the existing literature suggesting a positive association between CVD and different types of psychiatric disorders. In previous studies, an increased risk of depression13–15 and anxiety11 was noted after diagnosis of stroke,11,13–15 hypertension,17 coronary artery disease31 and atrial fibrillation.32 Such risk elevations has been suggested to be persistent over time,10,33,34 and, in parallel with our findings, associated with compromised survival.8,35,36 However, the evidence from prospective cohort studies with a long and complete follow-up as well as with a thorough control of confounding factors and comorbid conditions has, up to this point, been limited. Our study therefore complements previous findings revealing a positive association between a broader range of CVDs and subsequent risk of incident psychiatric disorder, using a large cohort with control of various confounding factors. We found the association to be robust both in sibling and population comparisons, and after additional adjustment for various comorbidities including other additional CVDs, indicating that the association is unlikely explained by shared familial factors and various comorbidities. We showed that CVD patients with psychiatric comorbidity was associated with an increased risk of subsequent CVD death, highlighting the importance of surveillance and prevention on psychiatric comorbidities for those newly diagnosed CVD patients.

The association between CVD and psychiatric disorders was noted both in men and women, across all age groups and calendar periods, as well as among individuals with or without a history of somatic diseases and family history of psychiatric disorders. Previous studies have indicated that major depression was more commonly recognized among individuals with multimorbidity (more than one CVD diagnosis) than those with only one condition.37 In our study, about 30% of the CVD patients developed one or more cardiovascular comorbidities during follow-up, and a higher risk of psychiatric disorder was indeed noted among patients with multiple CVD diagnoses. A compromised survival from CVD cause was indeed observed among most patients with common types of first CVD diagnosis and comorbid with psychiatric disorder.

Potential mechanisms

The pathophysiological mechanisms linking CVD and psychiatric disorders are complex and not well understood, and may vary with specific diagnoses of CVD and psychiatric disorders. The highly increased risk noted immediately after CVD diagnosis may indicate a direct impact of stress reaction of being diagnosed with a life-threatening disease.38 In addition, it has been proposed that biological alterations in the cardiovascular system to a severe stress response may increase the risk of various psychiatric disorders.39 For example, cardiovascular risk factors including hypercoagulability, dyslipidemia, and an impaired immune response have been associated with impaired psychological health.39 Some biological changes in patients with coronary heart disease (e.g., decreased heart rate variability, increased arterial stiffness, and endothelial dysfunction) have been observed in patients with depressive and anxiety disorders.40–42 Chronic inflammation may induce the development of atherosclerosis and arterial thrombosis, and elevation in inflammatory biomarkers (i.e., IL-6 and C-reactive protein) has been reported in various psychiatric disorders including post-traumatic stress disorder and major depression.43–45 Other behavioral and psychosocial factors may as well interact with these pathways and need to be understood further.

Conclusions

Using a large population-based sibling-controlled cohort with up to thirty years of follow-up, we demonstrate that patients with CVD have an increased risk of first-diagnosed psychiatric disorder, independent of familial background, history of somatic diseases, and other cardiovascular comorbidities. Our study further indicates an impact of psychiatric comorbidities on cardiovascular mortality among patients with CVD, motivating increased surveillance of psychiatric comorbidity among newly diagnosed patients with CVD.

Data Availability

Data analyses were performed in STATA 17.0 (StataCorp LP). STATA script used in the primary analyses has been made available as supplementary appendix. Aggregated data used for generating figures are available in supplementary appendix. The original data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. The authors are not able to make the dataset publicly available according to the Public Access to Information and Secrecy Act in Sweden. Any researchers (including international researchers) interested in accessing the data can send request to the authorities for data application by: 1) apply for ethical approval from local ethical review board; 2) contact the Swedish National Board of Health and Welfare (https://bestalladata.socialstyrelsen.se/, email: registerservice{at}socialstyrelsen.se) and/or Statistics Sweden (https://www.scb.se/vara-tjanster/bestall-data-och-statistik/, email: scb{at}scb.se) with the ethical approval and submit a formal application for access to register data. The same contacts can be used for detailed information about how to apply for access to register data for research purposes."

Competing interest

The authors declare that there is no conflict of interest.

Author Contributions

Drs Shen, Fang, and Valdimarsdóttir had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data.

Concept and design: Shen, Fang, and Valdimarsdóttir.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Shen, Fang, and Valdimarsdóttir.

Statistical analysis: Shen, Song, Fang, and Valdimarsdóttir.

Obtained funding: Fang, Valdimarsdóttir and Sullivan.

Administrative, technical, or material support: Shen, Fang, Valdimarsdóttir, Yu and Ye.

Supervision: Fang and Valdimarsdóttir.

Role of the Funder

The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, or approval of the manuscript; and decision to submit the manuscript for publication.

Ethical approval

The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32). Informed consent to each participant was waived by Swedish law in nationwide registry data.

Data availability statement

Data analyses were performed in STATA 17.0 (StataCorp LP). STATA script used in the primary analyses has been made available as supplementary appendix. Aggregated data used for generating figures are available in supplementary appendix. The original data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. The authors are not able to make the dataset publicly available according to the Public Access to Information and Secrecy Act in Sweden. Any researchers (including international researchers) interested in accessing the data can send request to the authorities for data application by: 1) apply for ethical approval from local ethical review board; 2) contact the Swedish National Board of Health and Welfare (https://bestalladata.socialstyrelsen.se/, email: registerservice{at}socialstyrelsen.se) and/or Statistics Sweden (https://www.scb.se/vara-tjanster/bestall-data-och-statistik/, email: scb{at}scb.se) with the ethical approval and submit a formal application for access to register data. The same contacts can be used for detailed information about how to apply for access to register data for research purposes.”

Transparency declaration

UV affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Supplementary Appendix

View this table:
Table S1. Summary of prospective cohort studies addressing the association between various indications of cardiovascular disease and risk of psychitric disorders/psychiatric symptoms.
Figure S1.
Figure S1. Study design

CVD: cardiovascular disease.

* 67 745 families had more than one sibling affected by CVD.

View this table:
Table S2. International Classification of Diseases (ICD) codes for exposure, outcome and covariates identifications.
View this table:
Table S3. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for incident psychiatric disorder among CVD patients compared with their full siblings or matched population controls, by patient characteristics
View this table:
Table S4. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for incident psychiatric disorders among CVD patients compared with their full siblings or matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)
Figure S2.
Figure S2. Crude incidence rates and hazard ratios with 95% confidence intervals (CIs) for an incident psychiatric disorder among different types of CVD patients compared with their full siblings or matched population controls, by number of CVD diagnoses during >=1 year of follow-upa

CVD: cardiovascular disease.

a Cox regression models, stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, and controlled for educational level, individualized family income, cohabitation status, as well as sex and birth year (in sibling comparison). Time since index date was used as underlying time scale. For patients with two or more CVD diagnoses, follow up time started from diagnosis of that cardiovascular comorbidity.

View this table:
Table S5. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for psychiatric disorders among CVD patients compared with their full siblings or matched population controls, excluding CVD patients medicated with psychotropic drugs, by time of follow-up (<1 or >=1 year from CVD diagnosis)a
View this table:
Table S6. Crude incidence rates (IRs) for psychiatric disorders among different groups of CVD patients, their full siblings and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)a
View this table:
Table S7. Crude incidence rates (IRs) of different types of psychiatric disorder among CVD patients, their full siblings, and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)
Figure S3.
Figure S3. Kaplan-Meier estimates of CVD death in CVD patients with and without incident psychiatric disorder during 1) six months or 2) two years of follow-up

CVD: cardiovascular disease.

a Time since index date was used as underlying time scale. 94.1% of CVD patients (N=817 748) survived the six months of follow-up and included in this analysis. The hazard ratio of cardiovascular death was 1.40 (95% confidence interval 1.27 to 1.54) when comparing CVD patients with psychiatric disorder to patients without such a psychiatric diagnosis (mortality rate, 8.1 and 7.0 per 1000 person-years, respectively).

b Time since index date was used as underlying time scale. 83.8% of CVD patients (N=728 179) survived the two years of follow-up and included in this analysis. The hazard ratio of cardiovascular death was 1.52 (95% confidence interval 1.43 to 1.62) when comparing CVD patients with psychiatric disorder to patients without such a psychiatric diagnosis (mortality rate, 9.1 and 7.4 per 1000 person-years, respectively).

Figure S4.
Figure S4. Kaplan-Meier estimates of CVD death in CVD patients with and without incident psychiatric disorder during the first year of follow-up, according to types of first CVD diagnosisa

CVD: cardiovascular disease.

a Time since index date was used as underlying time scale. 90.4% of CVD patients (N=785 287) survived the first year of follow-up and included in this analysis.

REFERENCS

  1. 1.↵
    Lu D, Andersson TML, Fall K, et al. Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden. JAMA Oncol. 2016;2(9):1188–1196. doi:10.1001/jamaoncol.2016.0483
    OpenUrlCrossRefPubMed
  2. 2.↵
    Shen Q, Lu D, Schelin MEC, et al. Injuries before and after diagnosis of cancer: nationwide register based study. BMJ. Published online August 31, 2016:i4218. doi:10.1136/bmj.i4218
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Zhu J, Fang F, Sjölander A, Fall K, Adami HO, Valdimarsdóttir U. First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study. Ann Oncol. 2017;28(8):1964–1969. doi:10.1093/annonc/mdx265
    OpenUrlCrossRefPubMed
  4. 4.↵
    Lindén T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients: a case-control study. Stroke. 2007;38(6):1860–1863. doi:10.1161/STROKEAHA.106.471805
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in Heart Failure: A Meta-Analytic Review of Prevalence, Intervention Effects, and Associations With Clinical Outcomes. J Am Coll Cardiol. 2006;48(8):1527–1537. doi:10.1016/j.jacc.2006.06.055
    OpenUrlFREE Full Text
  6. 6.↵
    Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006;21(1):30–38. doi:10.1111/j.1525-1497.2005.00269.x
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Shemesh E, Yehuda R, Milo O, et al. Posttraumatic stress, nonadherence, and adverse outcome in survivors of a myocardial infarction. Psychosom Med. 2004;66(4):521–526. doi:10.1097/01.psy.0000126199.05189.86
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Doering LV, Moser DK, Riegel B, et al. Persistent comorbid symptoms of depression and anxiety predict mortality in heart disease. Int J Cardiol. 2010;145(2):188–192. doi:10.1016/j.ijcard.2009.05.025
    OpenUrlCrossRefPubMed
  9. 9.↵
    Wrenn KC, Mostofsky E, Tofler GH, Muller JE, Mittleman MA. Anxiety, anger, and mortality risk among survivors of myocardial infarction. Am J Med. 2013;126(12):1107–1113. doi:10.1016/j.amjmed.2013.07.022
    OpenUrlCrossRefPubMed
  10. 10.↵
    Lincoln NB, Brinkmann N, Cunningham S, et al. Anxiety and depression after stroke: a 5 year follow-up. Disabil Rehabil. 2013;35(2):140–145. doi:10.3109/09638288.2012.691939
    OpenUrlCrossRefPubMed
  11. 11.↵
    Morrison V, Pollard B, Johnston M, MacWalter R. Anxiety and depression 3 years following stroke: demographic, clinical, and psychological predictors. J Psychosom Res. 2005;59(4):209–213. doi:10.1016/j.jpsychores.2005.02.019
    OpenUrlCrossRefPubMed
  12. 12.↵
    Romanelli J, Fauerbach JA, Bush DE, Ziegelstein RC. The significance of depression in older patients after myocardial infarction. J Am Geriatr Soc. 2002;50(5):817–822. doi:10.1046/j.1532-5415.2002.50205.x
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Wium-Andersen IK, Wium-Andersen MK, Jørgensen MB, Osler M. Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish patients. J Psychiatry Neurosci JPN. 2017;42(5):320–330. doi:10.1503/jpn160244
    OpenUrlAbstract/FREE Full Text
  14. 14.
    Baccaro A, Wang YP, Candido M, et al. Post-stroke depression and cognitive impairment: Study design and preliminary findings in a Brazilian prospective stroke cohort (EMMA study). J Affect Disord. 2019;245:72–81. doi:10.1016/j.jad.2018.10.003
    OpenUrlCrossRef
  15. 15.↵
    Pohjasvaara T, Vataja R, Leppävuori A, Kaste M, Erkinjuntti T. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol. 2001;8(4):315–319. doi:10.1046/j.1468-1331.2001.00182.x
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Chang JC, Yen AMF, Chen HH, et al. Comorbid diseases as risk factors for incident posttraumatic stress disorder (PTSD) in a large community cohort (KCIS no.PSY4). Sci Rep. 2017;7:41276. doi:10.1038/srep41276
    OpenUrlCrossRef
  17. 17.↵
    Petersson S, Mathillas J, Wallin K, Olofsson B, Allard P, Gustafson Y. Risk factors for depressive disorders in very old age: a population-based cohort study with a 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 2014;49(5):831–839. doi:10.1007/s00127-013-0771-2
    OpenUrlCrossRef
  18. 18.↵
    Zhang X, Norton J, Carrière I, Ritchie K, Chaudieu I, Ancelin ML. Risk factors for lateonset generalized anxiety disorder: results from a 12-year prospective cohort (the ESPRIT study). Transl Psychiatry. 2015;5(3):e536. doi:10.1038/tp.2015.31
    OpenUrlCrossRef
  19. 19.↵
    Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009;164(1):331–343. doi:10.1016/j.neuroscience.2009.03.080
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    Kathiresan S, Srivastava D. Genetics of Human Cardiovascular Disease. Cell. 2012;148(6):1242–1257. doi:10.1016/j.cell.2012.03.001
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    Rødevand L, Bahrami S, Frei O, et al. Polygenic overlap and shared genetic loci between loneliness, severe mental disorders, and cardiovascular disease risk factors suggest shared molecular mechanisms. Transl Psychiatry. 2021;11(1):1–11. doi:10.1038/s41398-020-01142-4
    OpenUrlCrossRef
  22. 22.↵
    Kelishadi R, Poursafa P. A review on the genetic, environmental, and lifestyle aspects of the early-life origins of cardiovascular disease. Curr Probl Pediatr Adolesc Health Care. 2014;44(3):54–72. doi:10.1016/j.cppeds.2013.12.005
    OpenUrlCrossRefPubMed
  23. 23.↵
    Rokita KI, Dauvermann MR, Donohoe G. Early life experiences and social cognition in major psychiatric disorders: A systematic review. Eur Psychiatry J Assoc Eur Psychiatr. 2018;53:123–133. doi:10.1016/j.eurpsy.2018.06.006
    OpenUrlCrossRef
  24. 24.
    D’Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. Am J Public Health. 2013;103 Suppl 1:S46-55. doi:10.2105/AJPH.2013.301252
    OpenUrlCrossRefPubMed
  25. 25.↵
    Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi:10.1186/1471-2458-11-450
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Dillner J
    Ekbom A. The Swedish Multi-generation Register. In: Dillner J, ed. Methods in Biobanking. Vol 675. Methods in Molecular Biology. Humana Press; 2011:215–220. doi:10.1007/978-1-59745-423-0_10
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    Song H, Fang F, Arnberg FK, et al. Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. BMJ. 2019;365. doi:10.1136/bmj.l1255
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Nevriana A, Pierce M, Dalman C, et al. Association between maternal and paternal mental illness and risk of injuries in children and adolescents: nationwide register based cohort study in Sweden. BMJ. 2020;369. doi:10.1136/bmj.m853
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Longitudinell integrationsdatabas för sjukförsäkringsoch arbetsmarknadsstudier (LISA). Statistiska Centralbyrån. Accessed May 22, 2018. http://www.scb.se/vara-tjanster/bestalla-mikrodata/vilka-mikrodata-finns/longitudinella-register/longitudinell-integrationsdatabas-for-sjukforsakrings--och-arbetsmarknadsstudier-lisa/
  30. 30.↵
    Lambert PC, Royston P. Further Development of Flexible Parametric Models for Survival Analysis. Stata J Promot Commun Stat Stata. 2009;9(2):265–290. doi:10.1177/1536867X0900900206
    OpenUrlCrossRefWeb of Science
  31. 31.↵
    Rutledge T, Kenkre TS, Bittner V, et al. Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation. Int J Cardiol. 2013;168(3):2335–2340. doi:10.1016/j.ijcard.2013.01.036
    OpenUrlCrossRefPubMed
  32. 32.↵
    Baumgartner C, Fan D, Fang MC, et al. Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. J Am Heart Assoc. 2018;7(8). doi:10.1161/JAHA.117.007814
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    Zawadzka E, Domańska Ł. Assessment of select dimensions of patients’ emotional functioning at different time periods after stroke. Appl Neuropsychol Adult. 2014;21(2):87–93. doi:10.1080/09084282.2012.747959
    OpenUrlCrossRef
  34. 34.↵
    Berg A, Palomäki H, Lehtihalmes M, Lönnqvist J, Kaste M. Poststroke depression: an 18-month follow-up. Stroke. 2003;34(1):138–143. doi:10.1161/01.str.0000048149.84268.07
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    Cai W, Mueller C, Li YJ, Shen WD, Stewart R. Post stroke depression and risk of stroke recurrence and mortality: A systematic review and meta-analysis. Ageing Res Rev. 2019;50:102–109. doi:10.1016/j.arr.2019.01.013
    OpenUrlCrossRefPubMed
  36. 36.↵
    Boden R, Molin E, Jernberg T, Kieler H, Lindahl B, Sundstrom J. Higher mortality after myocardial infarction in patients with severe mental illness: a nationwide cohort study. J Intern Med. 2015;277(6):727–736. doi:10.1111/joim.12329
    OpenUrlCrossRefPubMed
  37. 37.↵
    Findley P, Shen C, Sambamoorthi U. Multimorbidity and persistent depression among veterans with diabetes, heart disease, and hypertension. Health Soc Work. 2011;36(2):109–119. doi:10.1093/hsw/36.2.109
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    Fang F, Fall K, Mittleman MA, et al. Suicide and Cardiovascular Death after a Cancer Diagnosis. N Engl J Med. 2012;366(14):1310–1318. doi:10.1056/NEJMoa1110307
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association. Circulation. Published online January 25, 2021. doi:10.1161/CIR.0000000000000947
    OpenUrlCrossRef
  40. 40.↵
    Sherwood Andrew, Hinderliter Alan L., Watkins Lana L., Waugh Robert A., Blumenthal James A. Impaired Endothelial Function in Coronary Heart Disease Patients With Depressive Symptomatology. J Am Coll Cardiol. 2005;46(4):656–659. doi:10.1016/j.jacc.2005.05.041
    OpenUrlFREE Full Text
  41. 41.
    Seldenrijk A, van Hout HPJ, van Marwijk HWJ, et al. Depression, Anxiety, and Arterial Stiffness. Biol Psychiatry. 2011;69(8):795–803. doi:10.1016/j.biopsych.2010.12.034
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Stein PK, Carney RM, Freedland KE, et al. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J Psychosom Res. 2000;48(4):493–500. doi:10.1016/S0022-3999(99)00085-9
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–460S. doi:10.1093/ajcn/83.2.456S
    OpenUrlAbstract/FREE Full Text
  44. 44.
    Sumner JA, Nishimi KM, Koenen KC, Roberts AL, Kubzansky LD. Posttraumatic Stress Disorder and Inflammation: Untangling Issues of Bidirectionality. Biol Psychiatry. 2020;87(10):885–897. doi:10.1016/j.biopsych.2019.11.005
    OpenUrlCrossRefPubMed
  45. 45.↵
    Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. doi:10.1038/nri.2015.5
    OpenUrlCrossRefPubMed
Back to top
Posted June 27, 2022.
Download PDF
Data/Code
Email
Cardiovascular disease and subsequent risk of psychiatric disorders: a nationwide sibling-controlled study
Qing Shen, Huan Song, Thor Aspelund, Jingru Yu, Donghao Lu, Jóhanna Jakobsdóttir, Jacob Bergstedt, Lu Yi, Patrick F. Sullivan, Arvid Sjölander, Weimin Ye, Katja Fall, Fang Fang, Unnur Valdimarsdóttir
medRxiv 2022.06.27.22276962; doi: https://doi.org/10.1101/2022.06.27.22276962
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area